(Q35647811)

9 August 2017

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis (English)

1 reference

9 August 2017

0 references

1 reference

1 reference

7

N Veziris

1 reference

9 August 2017

M Ibrahim

1

1 reference

9 August 2017

K Andries

2

1 reference

9 August 2017

N Lounis

3

1 reference

9 August 2017

A Chauffour

4

1 reference

9 August 2017

C Truffot-Pernot

5

1 reference

9 August 2017

V Jarlier

6

1 reference

9 August 2017

language of work or name

English

0 references

publication date

18 December 2006

1 reference

Antimicrobial Agents and Chemotherapy

9 August 2017

1 reference

9 August 2017

51

1 reference

9 August 2017

1011-1015

1 reference

9 August 2017

3

1 reference

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration

9 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

Severe or fatal liver injury in 50 patients in the United States taking rifampin and pyrazinamide for latent tuberculosis infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

New small-molecule synthetic antimycobacterials

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

Preventive chemotherapy of tuberculosis in Cornell model mice with combinations of rifampin, isoniazid, and pyrazinamide

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

[Prevention of resistance to rifampicin by pyrazinamide in experimental tuberculosis in the mouse]

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

Activities of pefloxacin and ofloxacin against mycobacteria: in vitro and mouse experiments

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

National survey to measure rates of liver injury, hospitalization, and death associated with rifampin and pyrazinamide for latent tuberculosis infection

12 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1803154

Experimental short-course preventive therapy of tuberculosis with rifampin and pyrazinamide

25 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17178794

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

[Sterilizing activity of the main drugs on the mouse experimental tuberculosis (author's transl)]

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/17178794

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1128/AAC.00898-06

1 reference

9 August 2017

1 reference

9 August 2017

1 reference